Loxo Oncology
David Hyman currently serves as Chief Medical Officer at both Eli Lilly and Company and Loxo@Lilly since January 2020. Prior to this role, David held various positions at Memorial Sloan Kettering Cancer Center from 2009 to January 2020, including Associate Member, Chief of Early Drug Development, Assistant Member, and Director of Developmental Therapeutics. David also completed a Medical Oncology Fellowship at Weill Cornell Medicine, where David later became an Associate Professor of Medicine. David's early career included a Medicine Residency at New York Presbyterian Hospital from July 2006 to July 2009. Education credentials include an MD from Joan & Sanford I. Weill Medical College of Cornell University and a BS in Biology from Brown University.